Northwestern Mutual Wealth Management’s VistaGen Therapeutics VTGN Stock Holding History

Northwestern Mutual Wealth Management’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9	Buy	+16	New	+$10	﹤0.01%	4084

Other funds holding VTGN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Northwestern Mutual Wealth Management's VTGN Position: Q1 2026 in Review

Northwestern Mutual Wealth Management opened a new position in VistaGen Therapeutics (VTGN) in Q1 2026: 16 shares worth $9. The stake represents ﹤0.01% of the portfolio and ranks #4084 among its holdings.

56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

Northwestern Mutual Wealth Management held 16 shares of VistaGen Therapeutics worth $9 as of Q1 2026.
VistaGen Therapeutics was a new Northwestern Mutual Wealth Management position in Q1 2026.
VistaGen Therapeutics made up ﹤0.01% of Northwestern Mutual Wealth Management's portfolio in Q1 2026, its #4084 holding.
56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on Northwestern Mutual Wealth Management's 13F filing for Q1 2026, filed 7 May 2026.